Recombinant VWF (Caplacizumab Biosimilar) antibody
The Humanized Monoclonal anti-VWF (Caplacizumab Biosimilar) antibody is suitable to detect VWF (Caplacizumab Biosimilar) in samples from Human. It has been validated for ELISA and WB.
Catalog No. ABIN7538061
$323.13
Plus shipping costs $50.00
Shipping to:
United States
Delivery in 7 to 10 Business Days
Quick Overview for Recombinant VWF (Caplacizumab Biosimilar) antibody (ABIN7538061)
Target
VWF (Caplacizumab Biosimilar)
Antibody Type
Recombinant Antibody
Reactivity
Human
Host
Humanized
Clonality
Monoclonal
Application
ELISA, Western Blotting (WB)
Grade
Research Grade
-
-
Expression System
- Mammalian cells
-
Purpose
- Caplacizumab Biosimilar - Anti-VWF A1 domain mAb - Research Grade
-
Characteristics
- Antibody Type: VH-VH
-
Purification
- Recombinant antibody expressed in mammalien cells and purified.
-
Purity
- > 85%
-
-
-
Restrictions
- For Research Use only
-
-
-
Buffer
- PBS buffer PH7.5
-
Storage
- -80 °C
-
Storage Comment
- store at -80°C
-
-
- VWF (Caplacizumab Biosimilar)
-
Target Type
- Biosimilar
-
Background
- Caplacizumab is a humanized anti-von Willebrand factor (vWF) nanobody. Caplacizumab inhibits the vWF-mediated platelet adhesion and prevents further microthrombi formation. Caplacizumab can be used for the research of thrombotic thrombocytopenic purpura (TTP).
-
CAS-No
- 915810-67-2
Target
-
You are here:
